Navigation Links
European Research Council supports search for regulators of tissue damage
Date:1/27/2012

There is more to fighting infection than just clearing the body of pathogens. As important as resisting infection, is limiting damage to the host's tissue caused, very frequently, by toxins produced by pathogens or by components of the host immune response that clears those pathogens. Indeed, it is the damage inflicted to different tissues and organs that, if uncontrolled, can lead to the lethal outcome of some infectious diseases.

The in-built capacity that an infected individual has to limit the extent of tissue damage caused by different pathogens, a phenomenon known as 'tolerance to infection', has fascinated Miguel Soares, a group Leader at the Instituto Gulbenkian de Cincia (IGC) in Portugal, for several years. Now, the European Research Council (ERC) has awarded his team an Advanced Grant of just over 2,2 million Euros, to investigate the mechanisms involved in this protective response. This line of research should identify and pave the way to the development of new therapeutic interventions, to quell the clinical outcome of various diseases.

Miguel Soares and his research team have already identified a restricted number of mechanisms, regulated by specific genetic programmes that control tissue damage in response to different types of infection. They have shown that these protective mechanisms are active for example against severe forms of malaria and severe sepsis. The researchers believe, however, that other protective mechanisms controlled by groups of so-called "protective genetic programmes" can act in a similar manner in the context of different diseases. Their aim is to identify these protective mechanisms, and describe how the genetic programs act, so that these may be targeted to treat a whole range of infectious diseases.

Says Miguel Soares, "Infectious diseases such as malaria and severe sepsis remain medical challenges today, acting as major killers across the globe. Our data suggest that one of the reasons for this is that current available therapy is directed almost exclusively at clearing the pathogens causing these diseases, with no regard to controlling tissue damage. Our research directly addresses the hypothesis that controlling tissue damage should also be considered as a crucial arm in fighting infectious diseases. We expect to identify therapeutic targets to obtain that effect".

The ERC Advanced Grants are awarded to "exceptional", established researchers, to "pursue ground-breaking, high-risk projects that open new directions in their respective research fields or other domains", on the basis of scientific excellence alone, across three research domains. In the 2011 competition, 294 of 2284 applications are to be funded (corresponding to a success rate of 12%).

Of the 20 applications from scientists working in Portugal, two were selected: Miguel Soares' team, in life sciences, and another in social sciences and humanities. This is only the second ERC Advanced Grant to be awarded to a senior life scientist working in Portugal, and both have gone to IGC researchers. Furthermore, of the 18 ERC grants awarded to scientists working in Portugal, across all research domains and all levels of funding (staring and advanced), seven have been awarded to IGC scientists.


'/>"/>

Contact: Ana Godinho
agodinho@igc.gulbenkian.pt
351-214-407-959
Instituto Gulbenkian de Ciencia
Source:Eurekalert  

Related biology news :

1. European Geosciences Union General Assembly, April 22-27, 2012, Vienna, Austria
2. Cell Therapeutics, Inc. Expects That the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
3. European mountain vegetation shows effects of warmer climate
4. DTU is participating in a European network on measurement of greenhouse gases
5. Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux
6. UK invests £75 million in European research infrastructure to support knowledge-based economy
7. EMBO awards Installation Grants to 7 European scientists
8. How does a plant survive with few mates or pollinators? A European herb has figured out its own way
9. New European project launched to address shortcomings in climate data
10. Misleading morphology: 3 European parasitoid wasp species are seasonal forms of just 1
11. Genomatix to partner in $41 million European epigenomics consortium
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
European Research Council supports search for regulators of tissue damage
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: